Faculty profile

Yangxin Fu

Back to faculty

Associate ProfessorOncology DeptUniversity of Alberta

Yangxin Fu

Associate Professor

Oncology Dept

Faculty of Medicine & Dentistry

University of Alberta

Edmonton, Alberta, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
11 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CCS), most recently in 2019.
Supervisor on 1 trainee award (1 CIHR), most recently in 2012.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

417

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Alberta profile.

Latest papers

Dedifferentiation in endometrial cancer is associated with HLA-I silencing that may be restored by IFN-γ.
The Journal of pathology · 2026
Ferroptosis as a novel targeted therapy in gynecological malignant tumors.
Discover oncology · 2026
KAT6B/A::KANSL1 uterine sarcoma - A case with recurrences following uterine morcellation and the development of primary cell line model.
Gynecologic oncology reports · 2026

All 26 publications

Latest funding

Role of RNA methyltransferase NSUN5 in glioblastoma
CCS · 2019 · Principal investigator
$200,000
Understanding the role of Notch signaling in ovarian cancer stem cells
CIHR · 2012 · Supervisor
$17,500

All 2 grants and awards

26 publications.

Dedifferentiation in endometrial cancer is associated with HLA-I silencing that may be restored by IFN-γ.

De Leo A, Wickenberg M, Grillini M, Coadǎ CA, Praveen Kumar P, Tong A, Key J, Kim H, Kommoss F, Carey M, Fu Y, Ceccarelli C, Tallini G, LaPointe P, Köbel M, Lee CH

The Journal of pathology2026Open Access

DOI: 10.1002/path.70102 PMID: 42535334

Ferroptosis as a novel targeted therapy in gynecological malignant tumors.

Yu C, Li Y, Fu Y, Yang R, Nakevska Z, Kumar PP, Tong AN, Yang N, Liu D, Chen C, Ouyang L, Xia Z

Discover oncology2026

DOI: 10.1007/s12672-026-04686-x PMID: 41824195

KAT6B/A::KANSL1 uterine sarcoma - A case with recurrences following uterine morcellation and the development of primary cell line model.

Chen L, Liu J, Nechala I, Praveen Kumar P, Ewanowich C, Levecchia M, Aubrey C, Fu Y, Lee CH

Gynecologic oncology reports2026

DOI: 10.1016/j.gore.2026.102168 PMID: 42502505

Establishment and characterization of preclinical models of human gynecologic tract carcinosarcomas demonstrates targetable FGFR1 alterations

Nelson K.Y. Wong, Marta Llauradó Fernández, Hannah Kim, Pooja Praveen Kumar, DuPreez Smith, James A. Key, Yen‐Yi Lin, Stanislav V. Volik, Alice Y. Tong, Stéphane Le Bihan, Colin C. Collins, Yangxin Fu, Hui Xue, Yuzhuo Z. Wang, Martin Köbel, Mark Stafford Carey, Cheng‐Han Lee

Translational Oncology2025Open Access

DOI: 10.1016/j.tranon.2025.102591 PMID: 41202566

Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer.

Cooper TT, Dieters-Castator DZ, Liu J, Siegers GM, Pink D, Veliz L, Lewis JD, Lagugné-Labarthet F, Fu Y, Steed H, Lajoie GA, Postovit LM

Journal of ovarian research202422 citationsOpen Access

DOI: 10.1186/s13048-024-01471-8 PMID: 39020428

Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.

Kumar PP, Smith D, Key J, Dong H, Ganapathysamy A, Maranda V, Wong NKY, Fernandez ML, Kim H, Zhang G, Ewanowich C, Hopkins L, Freywald A, Postovit LM, Köbel M, Fu Y, Vizeacoumar FS, Vizeacoumar FJ, Carey MS, Lee CH

Gynecologic oncology20244 citationsOpen Access

DOI: 10.1016/j.ygyno.2024.06.029 PMID: 38970843

Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.

Chen H, Lee LJ, Vincent KM, Xu Z, Liu J, Zhang G, Nakevska Z, Smith D, Lee CH, Postovit LM, Fu Y

Oncogene20244 citationsSenior author

DOI: 10.1038/s41388-024-03026-z PMID: 38594503

Chelerythrine induces apoptosis and ferroptosis through Nrf2 in ovarian cancer cells.

Zhou J, Wang Y, Fu Y, Lin Z, Lin H, Lv G, Kong N, Xin G, Zhou F, Qiu Z, Huang X

Cellular and molecular biology (Noisy-le-Grand, France)2024

DOI: 10.14715/cmb/2024.70.3.26 PMID: 38650145

RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma.

Zhou J, Kong YS, Vincent KM, Dieters-Castator D, Bukhari AB, Glubrecht D, Liu RZ, Quilty D, Findlay SD, Huang X, Xu Z, Yang RZ, Zhang L, Tang E, Lajoie G, Eisenstat DD, Gamper AM, Fahlman R, Godbout R, Postovit LM, Fu Y

Molecular oncology202325 citationsSenior authorOpen Access

DOI: 10.1002/1878-0261.13434 PMID: 37057706

Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.

Köbel M, Yang RZ, Kang EY, Al-Shamma Z, Cook LS, Kinloch M, Carey MS, Hopkins L, Nelson GS, McManus KJ, Vizeacoumar FS, Vizeacoumar FJ, Freywald A, Fu Y, Reuss DE, Lee CH

Gynecologic oncology20238 citations

DOI: 10.1016/j.ygyno.2023.09.016 PMID: 37820398

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Yangxin Fu

Research

Latest papers

Latest funding

Dedifferentiation in endometrial cancer is associated with HLA-I silencing that may be restored by IFN-&#x3b3;.

Ferroptosis as a novel targeted therapy in gynecological malignant tumors.

KAT6B/A::KANSL1 uterine sarcoma - A case with recurrences following uterine morcellation and the development of primary cell line model.

Establishment and characterization of preclinical models of human gynecologic tract carcinosarcomas demonstrates targetable FGFR1 alterations

Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer.

Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.

Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.

Chelerythrine induces apoptosis and ferroptosis through Nrf2 in ovarian cancer cells.

RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma.

Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.

Role of RNA methyltransferase NSUN5 in glioblastoma

Understanding the role of Notch signaling in ovarian cancer stem cells

Frequent collaborators

Lynne-Marie Postovit

Helen Steed

Cheng-Han Lee

Martin Koebel

Mark Carey

Gilles Lajoie

Laura Hopkins

Francois Lagugne-Labarthet

Sandra Davidge

Andrew Freywald

Yuzhuo Wang

Colin Collins

Roseline Godbout

Zainab Al-Shamma

Mary Kinloch

Gregg Nelson

Morgan Craig

Laleh Alisaraie

Jacek Tuszynski

Mark Nachtigal

Aly Karsan

Christa Aubrey

Michael Weinfeld

Stephen Pasternak

Franco Vizeacoumar

Dedifferentiation in endometrial cancer is associated with HLA-I silencing that may be restored by IFN-γ.